Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report

Shuluan Li; Pei Zhang; Tianyu Wang; Jie Wang; Jianchun Duan

doi:10.1111/1759-7714.14133

Thoracic Cancer (Dec 2021)

Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report

Shuluan Li,
Pei Zhang,
Tianyu Wang,
Jie Wang,
Jianchun Duan

Affiliations

Shuluan Li: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Shenzhen China
Pei Zhang: Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
Tianyu Wang: Department of Breast Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Shenzhen China
Jie Wang: Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
Jianchun Duan: Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

DOI: https://doi.org/10.1111/1759-7714.14133
Journal volume & issue: Vol. 12, no. 23
pp. 3273 – 3276

Abstract

Read online

Abstract The definitive efficacy of anaplastic lymphoma kinase (ALK) inhibitors in ALK positive lung squamous cell carcinoma (sqCC) patients remain unclear. Here, we report a case in which brigatinib had a therapeutic effect on ALK‐positive lung squamous cell carcinoma. The patient in this report was diagnosed with ALK‐positive lung squamous cell carcinoma with brain metastases, and received brigatinib after failure of first‐line chemotherapy. Response duration was approximately 11 months, with tolerable side effects. In conclusion, a good clinical effect was achieved in a patient with ALK positive lung squamous cell carcinoma who received treatment with an ALK inhibitor.

Published in Thoracic Cancer

ISSN: 1759-7706 (Print); 1759-7714 (Online)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://onlinelibrary.wiley.com/journal/17597714

About the journal

Abstract

Keywords